Lightlake Therapeutics (LLTP) 8.8700 $LLTP
Opiant Pharmaceuticals, Inc., Announces Ticker Symbol Change to "OPNT"
GlobeNewswire - Mon Mar 07, 3:05PM CST
Opiant Pharmaceuticals, Inc. ("Opiant"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the change of its OTCQB trading symbol from "LLTP" to "OPNT." The change will take effect at the start of trading on March 8, 2016.
Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma Limited's First Commercial Sale of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray in the U.S.
GlobeNewswire - Mon Mar 07, 7:00AM CST
Opiant Pharmaceuticals, Inc. ("Opiant" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the receipt of a $2.5 million milestone payment from Adapt Pharma Limited ("Adapt" following its first commercial sale of NARCAN(R) Nasal Spray in the U.S. NARCAN(R) Nasal Spray is the only U.S. Food and Drug Administration (FDA) approved, ready-to-use, nasal spray version of naloxone hydrochloride, indicated for the emergency treatment of known or suspected opioid overdose.
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan(R) (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
GlobeNewswire - Wed Jan 27, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has announced two national programs at the Clinton Health Matters Initiative Activation Summit to assist in efforts to address the growing risk of opioid overdose among American high school students.
Traders Look to Upside - Complementary Research on Kingfisher, Lafargeholcim, Yahoo Japan and Lightlake Therapeutics
ACCESSWIRE - Wed Jan 20, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Kingfisher PLC (OTC: KGFHY), Lafargeholcim Ltd. (OTC: HCMLY), Yahoo Japan Corp. (OTC: YAHOY) and Lightlake Therapeutics Inc. (OTC: LLTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
GlobeNewswire - Tue Jan 19, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has, in support of White House efforts to address the opioid overdose epidemic and a community forum in Knoxville, Tennessee, announced that it has reached an agreement to facilitate the purchase of NARCAN(R) Nasal Spray by offering its discounted public interest price to 62,000 agencies in state and local government and the non-profit sector.
Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania
GlobeNewswire - Wed Dec 23, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that an opioid antagonist drug will be tested in patients with Cocaine Use Disorder at the University of Pennsylvania. The study will be conducted by the Department of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, and is beginning recruitment in December 2015.
Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
GlobeNewswire - Tue Dec 15, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that it has received a $2 million milestone payment from Adapt Pharma Limited ("Adapt" . This milestone payment was triggered by the U.S. Food and Drug Administration ("FDA" approval of NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake's commercial partner. The FDA approved NARCAN(R) Nasal Spray on November 18, 2015. Lightlake also expects to receive a $2.5 million milestone payment from Adapt after the prospective first commercial sale of NARCAN(R) Nasal Spray in the United States.
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
GlobeNewswire - Thu Nov 19, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt" , Lightlake's partner.
Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status
GlobeNewswire - Fri Sep 25, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has had a New Drug Application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) for NARCAN(R) (naloxone hydrochloride) Nasal Spray and Priority Review has been granted. NARCAN(R) Nasal Spray had previously been granted Fast Track Designation by the FDA and Adapt submitted an NDA in July 2015.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray
PR Newswire - Wed Jul 29, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Narcan® (naloxone) Nasal Spray, an investigational drug intended to treat opioid overdose.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone.
Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" .
Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
PR Newswire - Mon Feb 09, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015.
Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
PR Newswire - Thu Dec 04, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for opioid overdose.
Drug Addiction - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44hwmz/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Gilead Sciences, Inc. - Aphios Corporation - Teva Pharmaceutical Industries Limited - Addex Therapeutics Ltd - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - Rottapharm SpA - Omeros Corporation - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Lightlake Therapeutics Inc. - SK Biopharmaceuticals Co., Ltd. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/44..._addiction
GILD: 83.18 (+1.39), TEVA: 51.30 (+0.32), OMER: 10.82 (-0.05)
Opiant Pharmaceuticals, Inc., Announces Ticker Symbol Change to "OPNT"
GlobeNewswire - Mon Mar 07, 3:05PM CST
Opiant Pharmaceuticals, Inc. ("Opiant"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the change of its OTCQB trading symbol from "LLTP" to "OPNT." The change will take effect at the start of trading on March 8, 2016. Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma Limited's First Commercial Sale of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray in the U.S.
GlobeNewswire - Mon Mar 07, 7:00AM CST
Opiant Pharmaceuticals, Inc. ("Opiant"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the receipt of a $2.5 million milestone payment from Adapt Pharma Limited ("Adapt" following its first commercial sale of NARCAN(R) Nasal Spray in the U.S. NARCAN(R) Nasal Spray is the only U.S. Food and Drug Administration (FDA) approved, ready-to-use, nasal spray version of naloxone hydrochloride, indicated for the emergency treatment of known or suspected opioid overdose. Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan(R) (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
GlobeNewswire - Wed Jan 27, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has announced two national programs at the Clinton Health Matters Initiative Activation Summit to assist in efforts to address the growing risk of opioid overdose among American high school students. Traders Look to Upside - Complementary Research on Kingfisher, Lafargeholcim, Yahoo Japan and Lightlake Therapeutics
ACCESSWIRE - Wed Jan 20, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Kingfisher PLC (OTC: KGFHY), Lafargeholcim Ltd. (OTC: HCMLY), Yahoo Japan Corp. (OTC: YAHOY) and Lightlake Therapeutics Inc. (OTC: LLTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
GlobeNewswire - Tue Jan 19, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has, in support of White House efforts to address the opioid overdose epidemic and a community forum in Knoxville, Tennessee, announced that it has reached an agreement to facilitate the purchase of NARCAN(R) Nasal Spray by offering its discounted public interest price to 62,000 agencies in state and local government and the non-profit sector. Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania
GlobeNewswire - Wed Dec 23, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that an opioid antagonist drug will be tested in patients with Cocaine Use Disorder at the University of Pennsylvania. The study will be conducted by the Department of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, and is beginning recruitment in December 2015. Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
GlobeNewswire - Tue Dec 15, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that it has received a $2 million milestone payment from Adapt Pharma Limited ("Adapt" . This milestone payment was triggered by the U.S. Food and Drug Administration ("FDA" approval of NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake's commercial partner. The FDA approved NARCAN(R) Nasal Spray on November 18, 2015. Lightlake also expects to receive a $2.5 million milestone payment from Adapt after the prospective first commercial sale of NARCAN(R) Nasal Spray in the United States. NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
GlobeNewswire - Thu Nov 19, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt" , Lightlake's partner. Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status
GlobeNewswire - Fri Sep 25, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has had a New Drug Application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) for NARCAN(R) (naloxone hydrochloride) Nasal Spray and Priority Review has been granted. NARCAN(R) Nasal Spray had previously been granted Fast Track Designation by the FDA and Adapt submitted an NDA in July 2015. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray
PR Newswire - Wed Jul 29, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Narcan® (naloxone) Nasal Spray, an investigational drug intended to treat opioid overdose. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone. Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" . Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
PR Newswire - Mon Feb 09, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015. Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
PR Newswire - Thu Dec 04, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for opioid overdose. Drug Addiction - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44hwmz/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Gilead Sciences, Inc. - Aphios Corporation - Teva Pharmaceutical Industries Limited - Addex Therapeutics Ltd - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - Rottapharm SpA - Omeros Corporation - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Lightlake Therapeutics Inc. - SK Biopharmaceuticals Co., Ltd. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/44..._addiction
GILD: 83.18 (+1.39), TEVA: 51.30 (+0.32), OMER: 10.82 (-0.05)
